City
Epaper

S Korea targets homegrown Covid-19 vax early next year

By IANS | Updated: February 22, 2021 19:45 IST

Seoul, Feb 22 South Korea could produce locally developed vaccines against the novel coronavirus early next year, the ...

Open in App

Seoul, Feb 22 South Korea could produce locally developed vaccines against the novel coronavirus early next year, the ICT minister said on Monday, as the country seeks to prepare for a drawn-out fight against the pandemic.

Minister of Science and ICT Choi Ki-young said the government will continue to support development of local vaccines against the virus even though the country has secured enough vaccines from foreign pharmaceutical companies, such as Pfizer, Moderna and AstraZeneca.

The country plans to roll out its COVID-19 inoculation program with AstraZeneca's vaccines Friday, while inoculation with Pfizer's vaccines will start Saturday. South Korea has secured enough coronavirus vaccines to inoculate 79 million people, higher than its population of 51.6 million.

"We don't know how long the vaccines will stay effective, and there could be many strains of the virus," Choi said in a briefing. "We can't simply rely on foreign vaccines."

"If we continue to support development of local vaccines, we will be able to respond faster to new diseases or virus strains."

Last week, the government said it would inject 131.4 billion won (US$118.4 million) this year to help local pharmaceutical companies conduct clinical trials on COVID-19 vaccines and treatment.

The minister said local pharmaceutical companies are currently developing synthetic antigen vaccines, DNA vaccines and a viral vector vaccine against the virus and that phase 3 clinical trials of a homegrown vaccine could take place at the end of this year if development goes as planned.

Choi, however, warned that there are numerous uncertainties as problems could arise in clinical trials.

He said it would be difficult to conduct phase 3 trials in South Korea as it would require a lot of COVID-19 patients and there could be cost-related challenges.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: seoulICTSouth KoreaRepublic of koreaPfizerPfizer inc.Delle poole
Open in App

Related Stories

EntertainmentBTS Make Grand Comeback With Concert in Seoul After 4 Years; Fans React on X

InternationalSouth Korea Halts Military Live-Fire Drills After Child Hit by Suspected Stray Bullet in Daegu

EntertainmentQueen of Tears Actor Kim Soo Hyun Set For 2026 Release Amidst Dating Scandal With Kim Sae Ron?

EntertainmentHappy Birthday V: BTS’ Kim Taehyung Celebrates His 30th Birthday; Members Pour in Heartfelt Wishes

InternationalSouth Korean Rocket Blast: Massive Explosion After Hanbit-Nano Rocket Fails During Launch at Alcantara Space Center in Brazil

Health Realted Stories

HealthChhattisgarh: African Swine Fever outbreak confirmed, 300 pigs culled

HealthDelhi HC Court strikes down FSSAI regulation on cattle feed as ultra vires

HealthStruggling With Body Pain? These Sleeping Positions Can Help You To Sleep Better

HealthSouth Africa sees upcoming summit as platform to bolster economic ties with India

HealthFood PLI scheme attracts Rs 9,207 crore investment, creates 3.29 lakh jobs